Press Releases
You will find all our regulatory press releases in the feed below. Enjoy and share all our other Asarina Pharma news in our regularly updated News Archive.
First patient in for landmark Tourette Syndrome study
2022-02-16 14:31
30 patients ranging from 12 to 45 years old will be taking part in a phase IIa proof-of-concept study at two major University Hospitals in Copenhagen -...
The phase IIa Tourette study will take place at the Danish National Center for Tourette at Herlev University Hospital, Scandinavia’s largest Tourette...
Asarina Pharma AB (publ) Q3 Report 2021 released
2021-11-25 08:00
FINANCIAL HIGHLIGHTS R&D HIGHLIGHTS Following an administrative delay from Region Hovedstaden (the Capital Region of Denmark) we expect to receive...
PMDD Phase IIb study, including post-hoc analysis showing ‘significant treatment effect’, published in Journal of Psychoneuroendocrinology
2021-09-28 12:30
Topline results for Asarina Pharma’s phase IIb study in Sepranolone for PMDD, released in April 2020, found that Sepranolone failed to meet its primary...
Administrative backlog at public authority causes short-term delay in Tourette study
2021-09-16 16:46
Asarina Pharma’s Clinical Trial Application for its phase IIa study in Tourette Syndrome was approved by the Danish Medical Agency in May 2021 and...
Asarina Pharma AB (publ) Q2 Report 2021 released
2021-08-19 08:00
FINANCIAL HIGHLIGHTS R&D HIGHLIGHTS MENSTRUAL MIGRAINE TOURETTE SYNDROME OCD For further information, please contact: Peter Nordkild, CEO Phone: +45...
CEO Peter Nordkild: “Obviously we had hoped for a different outcome. This solid clinical study unfortunately does not confirm the scientific hypothesis...
Asarina Pharma granted US patent for Sepranolone for Tourette syndrome, OCD and pathological gambling
2021-06-08 08:30
The new patent is valid until 2038. Tourette and OCD are common co-morbidities, both with strong compulsion mechanisms. In March 2021 Asarina Pharma shared...
Asarina Pharma obtains convertible loan for continued research on neurological conditions including Obsessive Compulsive Disorder
2021-05-31 18:00
The convertible loan supplements Asarina Pharma’s current financial resources and will be spent on further exploration of the potential of Sepranolone...
Asarina Pharma: Issuance of 700,000 warrants completed
2021-05-28 08:20
Each warrant gives the holder the right to subscribe to one new Asarina share at a fixed price of SEK 9.87 (150% of the average share price during the...